Ticker	Volume	Price	Price Delta
DJIA	15,318.20	+138.38	0.91%
S&P 500	1,651.81	+12.77	0.78%
Nasdaq	3,482.18	+30.05	0.87%

Ticker

Volume

Price

Price Delta

DJIA

15,318.20

+138.38

0.91%

S&P 500

1,651.81

+12.77

0.78%

Nasdaq

3,482.18

+30.05

0.87%

Ticker	Volume	Price	Price Delta
STOXX 50	2,700.93	-1.76	-0.07%
FTSE 100	6,374.21	+43.72	0.69%
DAX	8,229.51	+13.78	0.17%

Ticker

Volume

Price

Price Delta

STOXX 50

2,700.93

-1.76

-0.07%

FTSE 100

6,374.21

+43.72

0.69%

DAX

8,229.51

+13.78

0.17%

Ticker	Volume	Price	Price Delta
Nikkei	13,133.80	+126.55	0.97%
Hang Seng	20,966.90	-258.99	-1.22%
S&P/ASX 200	4,847.60	+33.25	0.69%

Ticker

Volume

Price

Price Delta

Nikkei

13,133.80

+126.55

0.97%

Hang Seng

20,966.90

-258.99

-1.22%

S&P/ASX 200

4,847.60

+33.25

0.69%

Watson Wins EU Approval to Buy Generic-Drug Maker Actavis

By Aoife White - 2012-10-05T15:20:00Z

Watson Pharmaceuticals Inc. (WPI), maker of the generic version of Lipitor cholesterol pills, won European Union approval to buy closely held drugmaker Actavis Group hf to create the third-largest global generic-drug maker.

The European Commission said the combined company would continue to face competition from a sufficient number of credible and strong rivals, according to an e-mailed statement today.

Parsippany, New Jersey-based Watson agreed in April to buy Actavis for 4.25 billion euros ($5.6 billion), expanding its reach in Europe and Asia.

To contact the reporter on this story: Aoife White in Brussels at awhite62@bloomberg.net.

To contact the editor responsible for this story: Anthony Aarons at aaarons@bloomberg.net.

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.